Start with the specific medicine
Peptides are chains of amino acids. That chemical category includes medicines with very different uses, evidence and approval status. A claim about “peptide therapy” cannot tell you whether a particular product is suitable, effective or legally available.
Where GLP-1 medicines fit
Semaglutide and tirzepatide are peptide medicines. Our initial coverage focuses on the services that provide access to these treatments, with clear distinctions between approved branded products and compounded preparations.
What does not belong in the same bucket
Orforglipron is a non-peptide small-molecule GLP-1 receptor agonist. NAD+ is a coenzyme, not a peptide. A service may advertise these alongside peptide therapies, but that does not make their biology or supporting evidence interchangeable.
Questions before exploring another therapy
Ask what the exact substance is, whether the exact product is approved for the proposed use, what evidence supports it and who is responsible for prescribing and dispensing. Do not use broad wellness language as a substitute for those answers.
Sources and scope
Read FDA’s guidance on unapproved GLP-1 drugs for product-status context. For clinical product information, use semaglutide labeling and tirzepatide labeling. This guide explains comparison questions; it is not a clinical treatment recommendation.